Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Monday, November 16
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Investing»Moleculin Biotech stock rises as AML drug trial shows promising results By Investing.com
    Investing

    Moleculin Biotech stock rises as AML drug trial shows promising results By Investing.com

    February 18, 20262 Mins Read


    Investing.com — stock rose 3.1% in premarket trading Wednesday after the company reported encouraging preliminary data from its ongoing pivotal Phase 2B/3 “MIRACLE” trial for its AML treatment candidate.

    The clinical-stage pharmaceutical company announced that its Annamycin drug, in combination with cytarabine, has shown a preliminary blinded complete remission (CR) rate that is 67% higher than historical cytarabine response rates in treating acute myeloid leukemia (AML). The blinded data from the first 30 subjects revealed a composite complete remission rate of 40%, consisting of a 30% complete remission rate and 10% complete remission with partial hematological recovery.

    Moleculin has treated 35 subjects to date with another 11 identified or in screening. The company expects to reach its first milestone of treating 45 subjects in Q1 2026, with data unblinding to follow shortly thereafter.

    “The blinded efficacy rates we’re seeing in MIRACLE are exceptionally encouraging,” said Walter Klemp, Chairman and CEO of Moleculin. “Even with the control arm included, these preliminary, blinded results substantially outperform historical outcomes for CR with cytarabine alone.”

    Notably, approximately 35% of the treated subjects represent patients who failed venetoclax regimens, a population considered particularly difficult to treat with second-line therapies. The company also highlighted the continued absence of cardiotoxicity in Annamycin, a significant advantage over traditional anthracyclines used in cancer treatment.

    The MIRACLE trial is a randomized, double-blind, placebo-controlled study evaluating Annamycin at two dosing levels (190 mg/m² and 230 mg/m²) in combination with cytarabine, compared to cytarabine plus placebo in patients who have had a single prior induction therapy.

    The company expects to complete the unblinding of the first 45 subjects in late Q2 2026, with recruitment for the second group of 45 subjects continuing uninterrupted.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleWill Bitcoin and Crypto Market Crash After Fed Signals?
    Next Article 3 Vanguard ETFs to Buy Hand Over Fist if the Stock Market Crashes in 2026

    Related Posts

    Investing

    NZD/INR Historical Data | New Zealand Dollar Indian Rupee

    October 30, 2026
    Investing

    GBP 2 Years IRS Interest Rate Swap Bond Chart (Live Data)

    October 27, 2026
    Investing

    USD/CNY Historical Data | US Dollar Chinese Yuan

    October 25, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Bitcoin

    Bd Multimedia : BD Multimedia devient TRACTIAL

    July 2, 2025
    Finance

    Lili’s Embedded Finance solution now available

    October 29, 2024
    Investing

    Deckers Outdoor stock target lifted, outperform rating on strong sales By Investing.com

    October 25, 2024
    What's Hot

    Bitcoin Bears Dominate On Binance, Why Is Funding Rate Positive?

    August 29, 2024

    Bitcoin Price Prediction Today: BTC Nears $80K After 18% Rally

    August 21, 2026

    Banzai International sees $66,048 stock sale by CP BF lending By Investing.com

    October 26, 2024
    Most Popular

    Cours ETF VanEck Vectors Bitcoin ETN – USD

    February 23, 2025

    Colorado Springs Utilities proposes $1.8B spending plan for 2025, including base rate hikes over next 5 years | Local/County Politics

    August 20, 2024

    UK’s prettiest seaside town where properties take the longest to sell | UK | News

    October 26, 2024
    Editor's Picks

    RAC shelves London float as owners opt for continuation vehicle

    September 22, 2026

    U.S. stock futures steady; earnings, retail sale data awaited By Investing.com

    February 10, 2026

    BTC cycle to top at $100k? Bitcoin MACD crossover gives clues for investors

    October 25, 2024
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.